All patients involved in the phase 1 trial of a personalized cancer vaccine for high-risk stage III/IV kidney cancer showed a successful anticancer immune response.
Nearly 60,000 people are diagnosed with oral cancer in the U.S. every year, according to the American Cancer Society, and the rate of new cases continues to rise.
NEW YORK - Indaptus Therapeutics, Inc. (NASDAQ:INDP), a clinical-stage biotechnology company with a market capitalization of approximately $13 million, has received authorization from Health Canada to ...
To counteract these challenges, novel strategies aim to restore the cancer immunity cycle. One approach involves directly injecting unadjuvanted influenza vaccines or drug-loaded oncolytic viruses ...